Disorders of prolactin and growth hormone secretion.
A large range of tests is now available to help us understand, diagnose and manage GH-related growth disorders. The traditional provocative tests of GH secretion will identify short children with severe GH deficiency. However, evidence is emerging that these pharmacological tests may not be sufficiently sensitive to identify some subjects with GH deficiency arising from neurosecretory disturbance of GH release. There is a need for a simple sensitive test that will detect subtle GH secretion of this type. hGRF administration is a reliable test of GH reserve and, when used in combination with conventional tests, may help to identify GH-deficient children with hypothalamic GRF deficiency. Whether the GH responses following GRF administration reflects physiological GH secretory activity needs to be established. The diagnosis of acromegaly is made on clinical grounds. The abnormal GH responses to glucose and TRH support the diagnosis, but by themselves should not be considered to be diagnostic of acromegaly. An elevated Sm C level also helps to establish the diagnosis, although Sm C concentrations may be elevated to the same degree in pregnancy and during puberty. The use of Sm C to monitor disease activity remains to be established. Circulating GRF levels should be measured in patients with acromegaly so that ectopic production of GRF can be identified.
D000172:Acromegaly / Q000209:etiology; D001120:Arginine; D003000:Clonidine; D004392:Dwarfism / Q000209:etiology; D005260:Female; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000172:deficiency / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D007037:Hypothyroidism / Q000150:complications; D007334:Insulin-Like Growth Factor I; D007676:Kidney Failure, Chronic / Q000150:complications; D007774:Lactation; D007980:Levodopa; D008297:Male; D008750:Methyldopa / Q000009:adverse effects; D005082:Physical Exertion; D010911:Pituitary Neoplasms / Q000378:metabolism; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*; D011433:Propranolol; D012110:Reserpine / Q000009:adverse effects; D012890:Sleep / Q000502:physiology; D013002:Somatomedins; D013973:Thyrotropin-Releasing Hormone
D013002:Somatomedins; D007980:Levodopa; D008750:Methyldopa; D013973:Thyrotropin-Releasing Hormone; D007334:Insulin-Like Growth Factor I; D012110:Reserpine; D011388:Prolactin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine; D011433:Propranolol; D003000:Clonidine